employee
Vladivostok, Vladivostok, Russian Federation
Vladivostok, Vladivostok, Russian Federation
employee
Vladivostok, Vladivostok, Russian Federation
Vladivostok, Vladivostok, Russian Federation
UDK 616.31 Стоматология. Заболевания ротовой полости и зубов
Subject. The subject of the study is indicators of humoral immunity after standard therapy for chronic generalized periodontitis in patients with type II diabetes mellitus. Objectives. The goal is to assess the levels of cytokines and secretory IgA in the gingival fluid of patients before and after standard treatment of chronic generalized periodontitis: interleukin 1 beta (IL-1β), tumor necrosis factor alpha (TNF-α), tumor necrosis factor beta (TNF-β), interleukin 12 (IL-12), and its subtypes P 40 and P 70, interleukin 17 (IL-17), interferon gamma (IFN-γ), interleukin 10 (IL-10), interleukin 4 (IL-4), interleukin 13 (IL-13), transforming growth factor beta 1 (TGF-β1) and secretory IgA (sIgA) in patients with chronic generalized periodontitis without concomitant pathology (group I) and with chronic generalized periodontitis and diabetes mellitus Type II (group II). Methodology. 96 patients were examined, of which: 47 people – group I, 49 people – group II. The control group consisted of healthy volunteers (30 people). The levels of the studied cytokines were determined by the sandwich version of enzyme-linked immunosorbent assay using specific reagents “R&D Diagnostics Inc” (USA) and sIgA – “IgA secretory-ELISA-BEST” (Russia). Results. In patients of all study groups with mild periodontitis, normalization of the levels of cytokines and secretory IgA was established after standard treatment. In groups of patients with moderate and severe severity of chronic periodontitis, persistence of mucosal immune dysfunction was recorded. Conclusions. The data obtained indicate the need to prescribe immunotropic therapy in patients with moderate and severe severity of chronic generalized periodontitis.
periodontitis, diabetes mellitus, IL-1β, TNF-α, TNF-β, IL-12, IL-17, IFN-γ, IL-10, IL-4, IL-13, TGF-β1, sIgA
1. Antonov I.I., Mudrov V.P., Nelyubin V.N., Muraev A.A., Ivanov S.Yu. Sovremennye vozmozhnosti i perspektivy immunotropnoy terapii hronicheskogo generalizovannogo parodontita. Medicinskaya immunologiya. 2021;23(5):1055-1068. [I.I. Antonov, V.P. Mudrov, V.N. Nelyubin, A.A. Muraev, S.Yu. Ivanov. Modern possibilities and prospects of immunotropic therapy of chronic generalized periodontitis. Med Immunol. 2021;23(5):1055-1068. (In Russ.)]. http://doi.org/10.15789/1563-0625-COA-2156
2. Balmasova I.P., Lomakin Ya.A., Babaev E.A., Carev V.N., Gabibov A.G., Smirnov I.V., Knorre V.D., Ovchinnikova L.A., Gnuchev N.V., Hurs E.N., Deev M.S., Kostin N.N., Arutyunov S.D. Fenomen «ekranirovaniya» indukcii citokinov mikrobiomom parodonta pri sochetanii parodontita s saharnym diabetom tipa 2. ACTA NATURAE. 2019;4(43):79-87. [I.P. Balmasova, Ya.A. Lomakin, E.A. Babaev, V.N. Tsarev, A.G. Gabibov, I.V. Smirnov, V.D. Knorre, L.A. Ovchinnikova, N.V. Gnuchev, E.N. Khurs, M.S. Deev, N.N. Kostin, S.D. Arutyunov. Phenomenon "screening" induction of cytokines by the periodontal microbiome when periodontitis is combined with type 2 diabetes mellitus. ACTA NATURAE. 2019;4(43):79-87. (In Russ.)]. http://doi.org/10.32607/20758251-2019-11-4-79-87
3. Zaharova N.B., Ostrovskaya L.Yu., Lysov A.V., Perov A.V., Gladilin G.P. Znachenie preanaliticheskoy stadii issledovaniya desnevoy zhidkosti. Vestnik medicinskogo instituta «REAVIZ». 2019;4:175-179. [N.B. Zakharova, L.Yu. Ostrovskaya, A.V. Lysov, A.V. Perov, G.P Gladilin. The importance of the preanalytical stage of studying gingival fluid. Bulletin of the medical institute "REAVIZ". 2019;4:175-179. (In Russ.)]. https://cyberleninka.ru/article/n/znachenie-preanaliticheskoy-stadii-issledovaniya-desnevoy-zhidkosti/viewer
4. Kopeckiy I.S., Pobozh'eva L.V., Shevelyuk Yu.V. Vzaimosvyaz' vospalitel'nyh zabolevaniy parodonta i obschesomaticheskih zabolevaniy. Lechebnoe delo. Parodontit i sistemnye zabolevaniya. 2019;2:7-12. [I.S. Kopetsky, L.V. Pobozheva, Yu.V. Shevelyuk. The relationship of inflammatory periodontal diseases and general somatic diseases. Medical business. Periodontitis and systemic diseases. 2019;2:7-12 (In Russ.)]. https://elibrary.ru/item.asp?id=41304797&ysclid=lb817gvprp404880536
5. Kryuchkov D.Yu., Romanenko I.G., Dzhereley A.A., Gorobec S.M. Osobennosti lecheniya generalizovannogo parodontita u bol'nyh s metabolicheskim sindromom. Krymskiy terapevticheskiy zhurnal. 2021;3:44-50. [D.Yu. Kryuchkov, I.G. Romanenko, A.A. Jerelei, S.M. Gorobets. Features of treatment of generalized periodontitis in patients with metabolic syndrome. Crimean Therapeutic Journal. 2021;3:44-50. (In Russ.)]. https://elibrary.ru/item.asp?id=47190241
6. Petruhina N.B., Zorina O.A., Shih E.V., Kartysheva E.V., Kudryavcev A.V. Prognasticheskaya model' dlya ocenki hronicheskogo generalizovannogo parodontita u pacientov s metabolicheskim sindromom. Vestnik RGMU. 2019;2:48-52. [N.B. Petrukhina, O.A. Zorina, E.V. Shikh, E.V. Kartasheva, A.V. Kudryavtsev. Prognostic model for assessing chronic generalized periodontitis in patients with metabolic syndrome. Bulletin of RSMU. 2019;2:48-52. (In Russ.)]. http://doi.org/10.24075/vrgmu.2019.026
7. Bunte K., Beikler T. Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases // Int J Mol Sci. – 2019;20(14):3394. https://doi.org/10.3390/ijms20143394
8. Hegde R., Awan K.H. Effects of periodontal disease on systemic health // Disease-a-month. – 2019;65(6):185-192. https://doi.org/10.1016/j.disamonth.2018.09.011
9. Mahilkar S., Malagi S., Soni A., Abraham D., Johnson L., Pattanshetti K. IL-17, A Possible Salivary Biomarker for Preterm Birth in Females with Periodontitis // J Obstet Gynaecol India. – 2021;71(3):262-267. https://doi.org/10.1007/s13224-021-01466-1
10. Villafuerte K.R.V., Dantas F.T., Taba M. Jr, Messora M., Candido dos Reis F.J., Carrara H.H.A., Martinez C.J.H., Gozzo T., Palioto D.B. Effects of non-surgical periodontal therapy on the cytokine profile in gingival crevicular fluid of breast cancer patients with periodontitis undergoing chemotherapy // Support Care Cancer. – 2021;29(12):7505-7513. https://doi.org/10.1007/s00520-021-06194-w
